


**Extracellular ATP and IL-23 form a local inflammatory circuit leading to the  
development of a neutrophil-dependent psoriasiform dermatitis**


Julio A. Diaz-Perez<sup>1,4</sup>, Meaghan E. Killeen<sup>1</sup>, Cara D. Carey<sup>1</sup>, Yin Yang<sup>1</sup>, Louis D. Falo Jr<sup>1,3</sup>,  
and Alicia R. Mathers<sup>1,2,\*</sup>

Departments of <sup>1</sup>Dermatology, <sup>2</sup>Immunology, and <sup>3</sup>Bioengineering. University of Pittsburgh  
School of Medicine. Pittsburgh, PA 15261. USA.


## Supplemental Data




**Figure S1. P2X7R signaling is necessary for the induction of acute psoriasiform inflammation induced by rIL-23 but not IMQ.** rIL-23 and IMQ were utilized to induce inflammation in P2X7R  $-/-$  mice or age-matched C57BL/6 (WT) mice. On day 6 skin samples were collected and stained with H&E. Epidermal thickness was quantitated. Bars represent the mean  $\pm$  SEM (n=6, combined from two independent experiments), ten independent high powered field (HPF) measurements were averaged from each mouse. Asterisks indicate a significant difference compared to WT mice treated with rIL-23. \*\*\* =  $p < 0.001$ .




**Figure S2. Titration of BzATP.** WT mice were injected daily for 4 d with BzATP (175  $\mu$ M, 350 $\mu$ M, or 700  $\mu$ M) in 100  $\mu$ l PBS in the presence or absence of POM1. On day 5 skin samples were collected and stained with H&E to assess histological phenotype, measure bar = 100  $\mu$ m (n=4).



**Figure S3. Specific blockade of the P2X7R inhibits the development of psoriasis-like lesions.** WT mice were treated daily with BzATP + POM1  $\pm$  A438079 (A4; 80  $\mu$ mol/kg), a competitive P2X7R antagonist that is inactive at other P2 receptors. On day 5 skin samples were collected and stained with H&E, measure bar = 100  $\mu$ m (n=4).



**Figure S4. Inflammatory infiltrate induced following P2X7R stimulation.** Expression of CD3, TCR $\beta$ , TCR  $\gamma\delta$ , CD127, CD11c, CD11b, LY6C, and LY6G (Gated on CD45<sup>+</sup> cells) on cutaneous inflammatory infiltrates following PBS or BzATP + POM1 treatments on day 5. Four mice per treatment group were divided into two tubes for staining. One representative of two independent experiments.



**Figure S5. IL-23/ATP inflammatory pathway.** ATP is released into the extracellular (eATP) microenvironment following initial trauma, stress, or cell death. Additionally, IL-23 can also lead to the secretion of eATP, likely following DC activation. eATP then activates the P2X7R stimulating a variety of signaling pathways, including the activation of the NLRP3 inflammasome and NF- $\kappa$ B translocation. Together these pathways induce the secretion of IL-1 $\beta$ , IL-6, and IL-23, which can then lead to the expression of IL-17. Moreover, there are likely P2X7R-independent pathways that lead to IL-17 expression following IL-23 secretion. For instance, the IL-1 $\alpha$  or IL-36 pathways may induce an alternative inflammatory circuit.

## **Supplemental Materials and Methods**

<b>Antibody</b>	<b>Clone</b>	<b>Dye</b>	<b>Manufacturer</b>
CD3	145-2C11	BUV395	BD Biosciences
CD127	A7R34	PE	eBiosciences
CD45.2	104	PerCP/Cy5.5	BD Biosciences
CD11b	M1/70	V450	BD Biosciences
CD11c	HL3	PE/Cy7	BD Biosciences
TCR $\beta$	H57-597	BV421	Biolegend
TCR $\lambda\delta$	GL3	PE/Cy7	Biolegend
Ly6C	HK1.4	Alexa 488	Biolegend
Ly6G	IA8	Alexa 647	Biolegend
IL-17a	TC11-18H10	V450	BD Biosciences
Lineage	CD3/GR-1/CD11b /B220/Ter-119	Fitc	Biolegend